...of origin PDUFA data 11/26/18 Mayne Pharma Group Ltd. (ASX:MYX) / HedgePath Pharmaceuticals Inc. (OTCQX:HPPI) SUBA-Itraconazole...

...oral SUBA-Itraconazole for >=16 weeks reduced target tumor burden by >30% in 62% of patients. SUBA-Itraconazole...
...lesions showed a >30% reduction. SUBA-Itraconazole was well tolerated. HedgePath has exclusive, U.S. rights to SUBA-Itraconazole...
...Fla. Mayne Pharma Group Ltd. (ASX:MYX), Melbourne, Australia Product: SUBA-Itraconazole ( Lonzanoc , SUBA Itraconazole , Subacap...

...HedgePath began the open-label, U.S. Phase IIb SCORING trial to evaluate 100 mg oral SUBA-Itraconazole twice...
...Fla. Mayne Pharma Group Ltd. (ASX:MYX), Melbourne, Australia Product: SUBA-Itraconazole ( Lonzanoc , SUBA Itraconazole , Subacap...

...Preliminary data from a U.K. pivotal pharmacokinetic study showed that a half-dose of SUBA-Itraconazole was bioequivalent...
...was bioequivalent to Sporanox itraconazole from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). Halcygen acquired SUBA-Itraconazole...
...the compound outside of Australia and New Zealand. HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Product: SUBA-Itraconazole...

...in cash, plus earn outs over six years. The deal gives HalcyGen full control over SUBA-Itraconazole...

...A pivotal study showed that SUBA-Itraconazole produced comparable pharmacokinetics to Sporanox itraconazole from Johnson & Johnson...
...itraconazole from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). Halcygen has exclusive worldwide rights to SUBA-Itraconazole...
...HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Product: Subazole (formerly SUBA-Itraconazole...

...Halcygen began a U.S. pivotal pharmacokinetic study to evaluate oral SUBA-Itraconazole and Sporanox itraconazole from Johnson...
...New Brunswick, N.J.). Halcygen has exclusive worldwide rights outside of Australia and New Zealand for SUBA-Itraconazole...
...HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Product: Subazole (formerly SUBA-Itraconazole...

...Itraconazole, the active ingredient in Subazole, inhibited proliferation of endothelial cells involved in tumor-angiogenesis and tumor...
...growth in vitro. HalcyGen has exclusive worldwide rights outside of Australia and New Zealand to Subazole...
...HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Product: Subazole (formerly SUBA-Itraconazole...

...HGN will begin a U.S. Phase III trial to compare Subazole vs. Sporanox itraconazole capsules from...
...New Brunswick, N.J.). HGN has exclusive worldwide rights outside of Australia and New Zealand for Subazole...
...HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Hospira Inc. (HSP), Lake Forest, Ill. Product: Subazole (formerly SUBA-Itraconazole...

...HGN began an open-label Phase II in 12 patients. HGN has exclusive rights to SUBA-itraconazole outside...
...this year. HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Hospira Inc. (HSP), Lake Forest, Ill. Product: SUBA-Itraconazole...